CALIFORNIA, US. June 4, 2026 – Sapyen, the world’s leading male fertility diagnostics company, today announced a long-term strategic partnership with My Surrogacy Journey, one of the most prominent and internationally recognised organizations in global surrogacy.
The partnership will see Sapyen become a key fertility testing partner to My Surrogacy Journey and its intended parents globally, supporting pathways spanning semen analysis, DNA fragmentation testing, and infectious disease screening.
The agreement represents a significant alignment between two organizations increasingly shaping the operational future of reproductive medicine internationally.
Historically, male fertility diagnostics and preservation have remained fragmented, clinic-bound, expensive, and operationally difficult to coordinate across borders. Those inefficiencies become substantially more pronounced within surrogacy, where intended parents frequently navigate multiple jurisdictions, laboratories, legal frameworks, clinical providers, and timelines simultaneously.
Both organizations believe the next era of fertility care will be defined not by isolated services, but by globally coordinated infrastructure capable of supporting patients seamlessly across countries, clinics, and reproductive pathways.
My Surrogacy Journey has emerged as one of the defining operators in international surrogacy, recognised for its highly curated global network, strong ethical positioning, patient advocacy, and ability to coordinate complex international journeys at scale. The organization has developed a significant reputation among intended parents and fertility professionals for bringing structure, transparency, and operational sophistication to a category historically characterised by inconsistency and fragmentation.
Sapyen has similarly become a defining infrastructure company within modern fertility diagnostics. The company supports leading fertility clinics, laboratory groups, and healthcare organizations internationally with advanced at-home semen analysis, DNA fragmentation testing, infectious disease screening, and reproductive preservation workflows.
Sapyen’s SPX72 stabilisation technology extends analyzable semen sample viability from approximately one hour to up to 72 hours, enabling laboratory-grade fertility diagnostics and preservation pathways to operate outside traditional clinic collection constraints.
“The historical fertility model was built around geography,” said Ash Ramachandran, Founder and CEO of Sapyen. “Patients travelled to infrastructure. The next generation of reproductive medicine will invert that entirely.”
The partnership will initially launch across the United States with both organizations expected to expand collaboration across broader fertility preservation and reproductive health initiatives over time.
“Surrogacy is one of the most operationally complex categories in reproductive medicine,” Ramachandran continued. “It requires coordination across clinicians, laboratories, legal teams, donors, intended parents, and international jurisdictions simultaneously. Infrastructure quality materially impacts patient outcomes in that environment.
“My Surrogacy Journey has built one of the most sophisticated and trusted platforms globally for navigating that complexity. They are not simply facilitating introductions. They are helping define the operational and ethical standard for modern surrogacy internationally.”
Ramachandran added that fertility diagnostics and preservation are increasingly becoming foundational rather than peripheral within reproductive care pathways.
“For decades, fertility testing and preservation were positioned as reactive services. By the time many patients entered the system, optionality had already narrowed. We believe that changes now. Earlier diagnostics, better biological data, and accessible preservation infrastructure will increasingly become standard entry points into reproductive medicine globally.”
Michael Johnson-Ellis, Co-founder and Co-CEO of My Surrogacy Journey said the partnership reflected a deliberate focus on building the strongest possible ecosystem around intended parents internationally.
“Our responsibility to intended parents extends far beyond guidance. We are building an ecosystem around them capable of supporting extraordinarily complex journeys with consistency, credibility, and care.
“Sapyen immediately distinguished itself with both its scientific credibility and operational capability to execute fertility diagnostics and preservation at international scale.
“Their infrastructure, laboratory integration, and long-term vision for modern fertility care make them an exceptionally strong partner for My Surrogacy Journey and for the families we support across the world.”
Wes Johnson-Ellis, Co-founder and Co-CEO of My Surrogacy Journey, added that cross-border fertility pathways increasingly require globally interoperable infrastructure rather than fragmented local solutions.
“Intended parents today are navigating fertility across multiple countries and healthcare systems simultaneously. That requires partners capable of operating with precision internationally. This partnership materially strengthens the level of fertility support available to intended parents navigating increasingly global reproductive pathways.”
The partnership further strengthens Sapyen’s growing international footprint across fertility diagnostics and reproductive preservation, following continued expansion across IVF clinic networks, laboratory groups, benefits providers, and reproductive health organizations globally.
